A protective role of platelet-activating factor in murine candidiasis

Infection and Immunity

Volumn 65, Issue 4, 1997, Pages 1321-1326

  Im, Suhn Young ^a   Choi, Jung Hwa ^a   Ko, Hyun Mi ^a   Han, Su Ji ^a   Chun, Soon Bai ^a   Lee, Hern Ku ^b   Ha, Tai You ^b  

^a Chonnam National University   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; FEMALE; HOST RESISTANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

EID: 0030992190     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.4.1321-1326.1997     Document Type: Article

References (59)

1. Aderka, D., H. Holtmann, L. Toker, T. Hahn, and D. Wallach. 1986. Tumor necrosis factor induction by Sendai virus. J. Immunol. 136:2938-2942.
2. Allendoerfer, R., D. M. Magee, J. G. Smith, L. Bonewald, and J. R. Graybill. 1993. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J. Infect. Dis. 167:1168-1172.
3. k strains of mice. Immunogenetics 22:585-591.
4. Ashman, R. B., and J. M. Papadimitriou. 1995. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol. Rev. 59:646-672.
5. Barral-Netto, M., R. Badaro, A. Barrai, R. P. Almeida, S. B. Santos, F. Badaro, D. Pedral-Sampaio, E. M. Carvalho, E. Falcoff, and R. Falcoff. 1991. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J. Infect. Dis. 163:853-857.
6. Beutler, B., N. Krochin, I. W. Milsark, A. Goldberg, and A. Cerami. 1986. Induction of cachectin (tumor necrosis factor) synthesis by influenza virus: deficient production by endotoxin-resistant (C3H/HeJ) macrophages. Clin. Res. 34:491a. (Abstract.)
7. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
8. Bodey, G. P. 1984. Candidiasis in cancer patients. Am. J. Mod. 77(Suppl. 4D):13-19.
9. Braquet, P., L. Touqui, T. Y. Shen, and B. B. Vargaftig. 1987. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39:97-145.
10. Brummer, E., C. J. Morrison, and D. A. Stevens. 1985. Recombinant and natural gamma Interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect. Immun. 49:724-730.
11. Bussolino, F., F. Breviario, C. Terra, M. Aglietta, A. Mantovani, and E. Dejana. 1986. Interleukin 1 stimulate platelet-activating factor production in cultured human endothelial cells. J. Clin, Invest. 77:2027-2033.
12. Camussi, G., M. Aglietta, R. Coda, F. Bussolino, W. Piacibello, and C. Tetta. 1981. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 42:191-199.
13. Camussi, G., F. Bussolino, G. Salvidio, and C. Baglioni. 1987. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J. Exp. Med. 166:1390-1404.
14. Casals-Stenzel, J. 1987. Protective effect of WEB2068, a novel antagonist of platelet-activating factor, in endotoxin shock. Eur. J. Pharmacol. 135:117-122.
15. Chignard, M., J. P. Le Couedic, M. Tence, B. B. Vargaftig, and J. Benveniste. 1979. The role of platelet-activating factor in platelet aggregation. Nature (London) 279:799-800.
16. Choi, I. H., T. Y. Ha, D. G. Lee, J. S. Park, J. H. Lee, Y. M. Park, and H. K. Lee. 1995. Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet activating factor. Clin. Exp. Immunol. 100:390-394.
17. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochern. 162:156-159.
18. Djeu, J. Y., D. K. Blanchard, A. L. Richards, and H. Friedman. 1988. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J. Immunol. 141:4047-4052.
19. Dofferhoff, A. S. M., M. T. Esselink, H. G. de Vries-Hospers, A. V. Zanten, V. J. J. Bom, J. Weits, and E. Vellenga. 1993. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumor necrosis factor by human monocytes. J. Antimicrob. Chemother 31:373-384.
20. Dubois, C., E. Bissonnette, and M. Rola-Pleszczynski. 1989. Platelet activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages: prevention by PAF-receptor antagonists and lipooxygenase inhibitors. J. Immunol. 143:964-970.
21. Floch, A., A. Rousseau, E. Hetier, F. Floch, P. E. Bost, and L Cavero. 1989. RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induccd hemoconcentration and TNF release. J. Lipid Mediators 1:349-360.
22. Garner, R. E., K. Rubanowice, R. T. Sawyen, and J. A. Hudson. 1994. Secretion of TNF-α by alveolar macrophages in response to Candida albicans mannan. J. Leukocyte Biol. 55:161-168.
23. Gonzalez-Crussi, F., and W. Hsueh. 1983. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am. J. Pathol. 112:127-135.
24. Hsueh, W., X. Sun, L. M. Rioja, and F. Gonzalez-Crussi. 1990. The role of the complement system in shock and tissue injury induced by tumor necrosis factor and endotoxin. Immunology 70:309-314,
25. Huang, L., X. Tan, S. E. Crawford, and W. Hsueh. 1994. Platelet-activating factor and endotoxin induced tumor necrosis factor gene expression in rat intestine and liver. Immunology 83:65-69.
26. Im, S.-Y., H.-M. Ko, Y.-S. Ko, J.-W. Kim, H.-K. Lee, T.-Y, Ha, H. B. Lee, S.-J. Oh, S. Bai, K.-C. Chung, Y.-B. Lee, H.-S. Rang, and S.-B. Chun. 1996. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res. 56:2662-2665.
27. 26a.Im, S.-Y., and H.-K. Lee. Involvement of NF-κB in PAF-mediated TNF-α expression. Submitted for publication.
28. Jeremias, J., A. Kalo-Klein, and S. S. Witkin. 1991. Individual differences in tumor necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans. J. Med. Vet. Mycol. 29:157-163.
29. Jouault, T., G. Lepage, A. Bernigaud, P.-A. Trinel, C. Fradin, J.-M. Wieruszeski, G. Strecker, and D. Poulain. 1995. β-1,2-Linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production. Infect. Immun. 63:2378-2381.
30. Kagaya, K., and Y. Fukazawa. 1981. Murine defense mechanism against Candida albicans infection. II Opsonization, phagocytosis, and intracellular killing of C. albicans. Microbiol. Immunol. 25:807-818.
31. Kagaya, K., T. Shinoda, and Y. Fukazawa. 1981. Murine defense mechanism against Candida albicans infection. I. Collaboration of cell-mediated and humoral immunities in protection against systemic C. albicans infection. Microbiol. Immunol. 25:647-654
32. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-358.
33. Kullberg, B. J., J. W. van't Wout, C. Hoogstraten, and R. van Furth. 1993. Recombinant Interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice, J. Infect. Dis. 168:436-443.
34. Kurlander, R. J., M. Hoffman, S. S. Kratz, and J. Gates. 1989. Comparison of the effects of IL-1α and TNF-α on phagocyte accumulation and murine antibacterial immunity. Cell Immunol. 123:9-22.
35. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772.
36. Marks, J. D., C. B. Marks, J. M. Luce, A. B. Montgomery, J. Turner, C. A. Mertz, and J. F. Murray. 1990. Plasma tumor necrosis factor in patients with septic shock. Motalily rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am. Rev. Respir. Dis. 141:04-47.
37. Mencia-Huerta, J. M., and J. Benveniste. 1979. Platelet-activating factor and macrophage. I. Evidence for the release from rat and mouse peritoneal macrophages and not from maslocytes. Eur. J. Immunol. 9:409-415.
38. Montrucchio, G., E. Lupia, E. Battaglia, G. Passerini, F. Bussolino, G. Emanuelli, and G. Camussi. 1994. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J. Exp. Med. 180:377-382.
39. Morrison, C. J., E. Brummer, R. A. Isenberg, and D. A. Stevens. 1987. Activation of murine polymorphonuclear neutrophils for fungicidal activity by recombinant gamma interferon. J. Leukocyte Biol. 41:434-440.
40. Nakane, A., T. Minagawa, and K, Kato. 1988. Endogenous tumor necrosis factor is essential to host resistance against Listeria monocytogenes infection. Infect. Immun. 56:2563-2569.
41. Nawroth, P. P., and D. M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740-745.
42. Ogata, M., T. Matsumote, K. Koga, I. Takenaka, M. Kamochi, T. Sata, S.-I. Yoshida, and A. Shigematsu. 1993. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect. Immun. 61:699-704.
43. Opal, S. M., A. S. Cross, N. M. Kelly, J. C. Sadoff, M. W. Bodmer, J. E, Palardy, and G. H. Victor. 1990. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J. Infect. Dis. 161:1148-1152.
44. Pecyk, R. A., E. B. Fraser-Smith, and T. R. Matthews. 1989. Efficacy of interteukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice. Infect. Immun. 57:3257-3258.
45. Pisa, P., M. Gennene, O. Soder, T. Ottenhoff, M. Hansson, and R. Kiessling. 1990. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J. Infect. Dis. 161:988-991.
46. Puccetti, P., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, K.-H. Enssle, L. Romani, and F. Bistoni. 1994. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. 169:1325-1331.
47. Redmond, H. P., J. Shou, H. J. Gallagher, C. J. Kelley, and J. M. Daly. 1993. Macrophage-dependent candidacidal mechanisms in the murine system: comparison of murine Kupffer cell and peritoneal macrophage candidacidal mechanisms. J. Immunol. 150:3427-3433.
48. Riipi, L., and E. Carlson. 1990. Tumor necrosis factor (TNF) is induced in mice by Candida albicans: role of TNF in fibrinogen increase. Infect. Immun. 58:2750-2754.
49. Romani, L., A. Mencacci, U. Grohmann, et al. 1992. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type I associated immunity in murine candidiasis. J. Exp. Med. 176:19-23.
50. Romani, L., P. Puccetti, A. Mencacci, E. Cenci, R. Spaccapelo, L. Tonnetti, U. Grohmann, and F. Bistoni. 1994. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J. Immunol. 152:3514-3521.
51. Smith, J. C., M. Magee, D. M. Williams, and J. R. Graybill. 1990. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma cap- sulatum. J. Infect. Dis. 162:1349-1353.
52. Steinshamn, S., and A. Waage. 1992. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect. Immun. 60:4003-1008.
53. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (London) 330: 662-664.
54. Tracey, K. J., H. Vlassara, and A. Cerami. 1989. Cachectin/tumor necrosis factor. Lancet i:1122-1125.
55. Valone, F. H., and L. B. Epstein. 1988. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-lβ tumor necrosis factor or IFN-γ. J. Immunol. 141:3945-3950.
56. van't Wout, J. W., I. Linde, P. C. Leijh, and R. van Furth. 1988. Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infection. Eur. J. Clin. Microbiol. Infect. Dis. 7:736- 741.
57. Voelker, N. F., S. Worthen, J. T. Reeves, and H. M. Henson. 1982. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 218:286-288.
58. Von Asmuth, E. J. U., J. G. Maessen, C. J. Van der Linden, and W. A. Buurman. 1990. Tumor necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Scand. J. Immunol. 32:313-319.
59. Zacharchuk, C. M., B.-E. Drysdale, M. M, Mayer, and H. H. Shin. 1983. Macrophage-mediated cytotoxicity: role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor. Proc. Natl. Acad. Sci. USA 80:6341-6345.